ClinicalTrials.gg
Not yet recruitingNCT07472907RESPLANDUpdated Oct 26, 2026

A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations

A Phase 1/2 interventional study of CIL001 (Paliroden) and Placebo in Cochlear Synaptopathy, sponsored by Cilcare SAS. Not yet recruiting. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Cilcare SAS · Phase 1/2, Interventional, and Treatment

Updated Oct 26, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

Like retinopathy, neuropathy and nephropathy, sensorineural hearing loss is a common and underserved complication of uncontrolled diabetes. Neuroinflammation in diabetes can cause auditory nerve damage (cochlear synaptopathy) which first translates into speech-in-noise intelligibility deficit. CIL001 is a neurotrophic small molecule that aims to repair auditory nerve when applied locally by transtympanic injection. Transtympanic injection of paliroden is anticipated to improve the symptoms of cochlear synaptopathy. Furthermore, by addressing auditory or vestibular dysfunction early and effectively, this approach may contribute to limiting or delaying, over the long term, the onset of secondary neurological disorders, such as dementia.

02

Conditions studied

  • Cochlear Synaptopathy

Browse trials for

Keywords

  • hearing
  • diabetes
03

In context

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

This study's planned enrollment of 135 is above the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Cilcare SAS is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated form
  2. Aged between 45 and 75 years old (inclusive) at the time of screening
  3. Established type 2 diabetes as determined by 7% ≤ (HbA1c) ≤ 9% and diabetes duration of at least 5 years
  4. Be considered as reliable and capable of adhering to the protocol, according to the judgment of the Investigator
  5. Participants must be native speakers of the official language(s) of the country in which the study assessments are conducted.
  6. Women of (WOCBP) must have a negative serum pregnancy test upon entry into this study. In addition, they must agree to use highly effective methods, as defined by regulatory guidance (e.g., combined hormonal contraception, intrauterine device, or surgical sterilization), from the screening visit, for the duration of study treatment and for 30 days after dosing.

    The following audiology assessments, if not performed on the same day as the review of the previous criteria (e.g., when the participant's first visit does not take place at the ENT site), may be scheduled on different days within a maximum interval of 14 days after the first screening visit and must be completed at least 21 days before the baseline visit.

  7. Normal hearing as defined by PTAv (0.5-1-2kHz-4Khz) \<25dB in both ears.
  8. Up to mild hearing loss in the high-frequency range (PTAvHF (4-6-8kHz) \<40dB) in both ears.
  9. Speech-in-noise deficit (at least 3dB SNR loss in comparison to normative value of the Matrix test) in both ears.

Exclusion criteria

Exclusion Criteria:

  1. score \< 26
  2. Known otologic pathology (e.g., History of hearing loss, radiation-induced hearing loss, fluctuating hearing, endolymphatic hydrops, or Menière's disease in either ear)
  3. Presence of middle ear pathology (e.g., otitis media, tympanic membrane perforation, etc.)
  4. History of platinum-based chemotherapy
  5. Previous or concurrent that require treatment and are not clinically stable
  6. Current evidence or history of retrocochlear pathology (e.g., acoustic neuroma)
  7. History of otologic surgery (apart from tympanostomy tube insertion if more than one year prior to inclusion visit)
  8. Abnormal otoscopy as defined by less than 90% of the tympanic membrane visible (e.g., cerumen ear plug, ear drum perforation). In case of cerumen plugs not affecting the hearing results, a removal must be scheduled before V1 (baseline/inclusion).
  9. Hearing aids and cochlear implants.
  10. History of cancer treated by platinum-based chemotherapy.
  11. Lactation or known pregnancy or positive pregnancy test at both screening and baseline for women of , or planning to become pregnant during the study
  12. Liver Enzyme Lab Outcomes:

    1. > 2 times the (ULN)
    2. (ALT) or aspartate aminotransferase (AST) (AST/ALT) >5 times ULN.
    3. Gamma glutamyltransferase (GGT) > 5 times ULN
  13. Maternally Inherited Diabetes
  14. Congenital hearing loss
  15. Untreated hypothyroidism
  16. Adult individual under legal protection as defined by applicable regulations (e.g., persons deprived of liberty, hospitalized without consent, unable to provide , or placed under legal guardianship or curatorship)
  17. Concurrent participation in another clinical study or participation in another trial involving experimental drug within 30 days or five half-lives of the experimental drug (whichever was longer) prior to screening visit (V0).
  18. Diagnosed anxiety disorders, psychosis, depression, schizophrenia, attempted suicide, or other significant psychiatric conditions that could impact their ability to cooperate and comply with the study protocol
  19. Major surgery that may impact the study conduct or outcomes within eight weeks before screening or scheduled/planned surgery within the time frame of the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    CIL001

    Single Unilateral transtympanic administration

    Drug: CIL001 (Paliroden)

  • Placebo comparator
    Placebo

    Single Unilateral transtympanic administration

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Frequencies of Treatment-Related Adverse Events with a particular focus on ear and auditory symptomatology

    Time frame: Over 6 month (168 days) post-injection

Secondary outcomes

  1. Determine the concentration in plasma of paliroden with Area under the plasma concentration versus time curve (AUC)

    Time frame: From the day of injection to 28 days

  2. Determine the concentration in plasma of paliroden with Peak Plasma Concentration (Cmax)

    Time frame: From the day of injection to 28 days

  3. Determine the concentration in plasma of paliroden with Time to maximum concentration (Tmax)

    Time frame: From the day of injection to 28 days

  4. Change in speech in noise intelligibility base on the SRT50 result From the Matrix test (SRT50 = Signal-to-noise ratio required to correctly understand 50% of presented speech)

    Time frame: At Day 84 from baseline

  5. Change in ABR Wave I amplitude (µV) measured by electrocochleography

    Time frame: Day 28, Day 84, Day 168

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 40 phase 1/2 interventional studies under Diabetes Mellitus, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 11 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Aug 2026 → Jan 2027, primary completion Jul 2027 → Dec 2027 and completion Dec 2027 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 16, 2026
StartEst.
Jan 2027was Aug 2026
Primary completionEst.
Dec 2027was Jul 2027
CompletionEst.
Jul 2028was Dec 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Jan 2027
Oct 26, 2026
Primary completion
Jul 2027→Dec 2027
Oct 26, 2026
Study completion
Dec 2027→Jul 2028
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Aug 2026→Jan 2027
    Primary completion Jul 2027→Dec 2027
    Study completion Dec 2027→Jul 2028
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07472907
Lead sponsor
Cilcare SAS
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliroden

Start the discussion